Medicine Description fraxiparine 2850i
Fraxiparine 2850 I.U. prefilled syringe is a medication that contains nadroparin, a low molecular weight heparin. Its primary mechanism of action involves the inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin), which are crucial components in the coagulation cascade. By binding to antithrombin III, nadroparin enhances its inhibitory effect on these clotting factors, leading to a reduction in thrombin generation and the overall clotting process. This anticoagulant effect helps to prevent the formation of blood clots, making it effective in the management of thromboembolic disorders.
Indications and Uses of Fraxiparine 2850 I.U. prefilled syringe
- Prevention of deep vein thrombosis (DVT) following major surgeries, particularly orthopedic procedures such as hip or knee replacements.
- Treatment of acute venous thromboembolism, including deep vein thrombosis and pulmonary embolism.
- Management of unstable angina and non-Q wave myocardial infarction as part of a broader treatment strategy.
Side Effects of Fraxiparine 2850 I.U. prefilled syringe
- Bleeding complications
- Injection site reactions
- Thrombocytopenia (low platelet count)
- Allergic reactions
- Elevation of liver enzymes
Storage and Handling
Store at 2°C to 8°C (36°F to 46°F) in its original packaging to protect from light. Do not freeze. Discard any unused medication after the expiration date.
Patient Advice and Precautions
Patients should be advised to report any signs of unusual bleeding or bruising. It is important to inform healthcare providers of all medications being taken to avoid potential interactions. Regular monitoring of blood parameters may be necessary during treatment. Patients should be instructed on proper injection techniques if self-administering.